Member Info for Bladderman

Targetted patient therapy (sub population targetting) is what the medical regulatory body and BIG pharma are all about. JV coming for the 'extremly' positive response in this patient sub set (30% of ARDS!!)

Stock under 100p will be like gold dust. We know the Japanese data will be shit but with the acquired knowledge i bet they've sampled the trial patient and are doing PCR to target the mutation group. They've already told us n doesnt work for 90% of Asians. However, it does in 30% Caucasians and 50% of Africans!! Then Clevegen. Boom boom

Oh look. She's blue...

Exactly Spike. This is going to be special...

Stock is so tightly held and the MMs becoming hungray as hell for it. Stock drying up under 80p...

This should be trading 100p plus on yesterdays news EASY

Yesterdays must see Proactive vid... https://youtu.be/4VoKj6svUiw

If the seller has finished or the manipulation over this is going to fly..

No surprise. Some folk will be locked out on the way up...

The SP will rerate to the upside as the market digests and understands the significance of this painfully undervalued gem. Watch this space..

Markets are awful at the moment but that will not stop the lucrative partnership from happening because there is a medical need/demand for ARDS treatment which has to be met so WILL be fast tracked.

This was a £300M company before it tanked. Now has a very effective ARDS treatment for 30% of ALL sufferers and worth less than 10% of that value.. There is NO other effective treatment. Significant partners who remained in coms will now be extremly interested as a consequence of this highly significant and positive trial development/outcome and identification of this unique 30% patient pool therapeutic. A JV is coming guys...

We're not talking cell culture or murine efficacy - this is legitimate human profiling with very limited toxicity and very impressive efficacy. Those talking about other compounds are talking shit. Screw cell culture and potential mkise modelling with othe candidates ..most never make stage III - let alone human efficacy. Make up your own mind ha. Now officially one of THE most undervalued stocls on AIM - although is not an AIM company by definition ha

It's ridiculous mate. To think peps were expecting 1200p a share on 100% efficacy. We're at 30% in caucausian market and valued at 80p - s**t the bed lol. Should be 150p.by friday end of play

Be lucky to buy under 80p. Plenty will reaearch tonight and realise that not 3% instead 30% are suitable for this 'very effective' ARDS therapy. That'a incredible and the regulatora will love the targettes therapeutic landacape. Bring it on!!

8% royalty lol. So £200M per annum to someone else lol. £4k a pop prob more like £20k!!

Full Ask getting slapped. Strong finish today and gap up tomorrow will do nicely!

Sub population patient group targetted therapy. The regulators are going to love this compound - as will the JV partners!

Should be a nice afternoon push on the cards...

At this minute sure